Placebo News and Research

RSS

QRxPharma, Actavis enter License and Option Agreement

QRxPharma Limited announced today execution of its License and Option Agreement with Actavis, Inc. which finalised the legal terms and conditions to commercialise MoxDuo IR in the US acute pain marketplace. The LOA completion follows a 20 December 2011 signing of a binding Letter of Intent secured by a US$6 million non-refundable upfront signing fee to QRxPharma.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Americans looking to impact their cold and flu symptoms this season may have a new weapon at their disposal. A randomized, double-blind, placebo-controlled study just published by the University of Florida determined that Kyolic Aged Garlic Extract (AGE) may reduce the duration of symptoms associated with common colds or flus by as much as 61 percent.

16 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

16 Mar 2012

Scale to measure potential harm caused by invasive placebos in local anaesthesia research

A scale developed to measure the potential harm caused by invasive placebos in local anaesthesia research has been successfully tested by a group of 43 independent clinicians, according to research published in the April issue of Anaesthesia.

15 Mar 2012

Fear of flying can be cured independently of YOH or after 4 sessions of VRET

This randomized controlled trial shows that fear of flying can be cured independently of drug condition [yohimbine hydrochloride (a noradrenaline agonist) or placebo] after 4 sessions of virtual reality exposure therapy (VRET).

15 Mar 2012

Combined therapy effective in treating patients with severe facial acne

A combined therapy of common acne medications was shown to be a potent regimen for treating patients with severe facial acne, according to two published studies involving Henry Ford Hospital.

15 Mar 2012

New topical gel decreases amount of time needed to treat actinic keratosis

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine.

15 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

Earlier start of micronutrient supplementation better for pregnant women and the unborn child

When pregnant women take supplements with micronutrients (vitamins and minerals), the growth of their unborn child improves. The improvement is cumulative, so researchers from the Antwerp Institute of Tropical Medicine report : the earlier in pregnancy the supplementation starts, the better. In developing countries, where women often have a poor diet, these supplements really make a difference.

14 Mar 2012

Botox - a potential for therapy of weak bladders in women

The study, published in the journal European Urology, was carried out at eight uro-gynecology centers in the UK from 2006 to 2009 by researchers from the University of Leicester. A total of 240 women were split into two groups, with 122 women given Botox and 118 receiving a dummy treatment. Researchers found improvements across a range of symptoms, including wetting oneself and feeling a need to rush to the toilet, and how often the women 'leaked' urine.

13 Mar 2012

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of patients in its phase 2 clinical study of RP503 for schizophrenia and schizoaffective disorder.

13 Mar 2012

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has commenced a Phase I clinical trial in healthy adults in Paris, France, to determine the safety and tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to treat human African trypanosomiasis (HAT, or sleeping sickness) for stage 1 and stage 2 of the disease.

12 Mar 2012

HemaQuest closes $13 million extension of Series B financing

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has closed a $13 million extension of their Series B financing.

12 Mar 2012

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Watson Pharmaceuticals, Inc. today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical intervention.

12 Mar 2012

Placebo News and Research

QRxPharma, Actavis enter License and Option Agreement

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

Tarsa advances OSTORA NDA filing through $28M Series B financing

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Kyolic AGE may reduce duration of cold and flu symptoms by 61%

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

CSL Behring initiates FCH Phase III trial to control bleeding during cardiovascular surgery

Scale to measure potential harm caused by invasive placebos in local anaesthesia research

Fear of flying can be cured independently of YOH or after 4 sessions of VRET

Combined therapy effective in treating patients with severe facial acne

New topical gel decreases amount of time needed to treat actinic keratosis

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Earlier start of micronutrient supplementation better for pregnant women and the unborn child

Botox - a potential for therapy of weak bladders in women

Reviva to initiate enrollment in RP503 phase 2 study for schizophrenia

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

HemaQuest closes $13 million extension of Series B financing

Watson commences Esmya Phase 3 trial in women with anemia linked to uterine leiomyomas

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News